Announcements
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
- Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
- Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
- Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
- Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
- Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
- Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
- Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
More ▼
Key statistics
On Thursday, Eledon Pharmaceuticals Inc (2TK:BER) closed at 1.85, -26.59% below its 52-week high of 2.52, set on May 11, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.85 |
---|---|
High | 1.85 |
Low | 1.85 |
Bid | -- |
Offer | -- |
Previous close | 1.86 |
Average volume | 111.11 |
---|---|
Shares outstanding | 24.20m |
Free float | 22.85m |
P/E (TTM) | -- |
Market cap | 49.85m USD |
EPS (TTM) | -5.59 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:06 BST.
More ▼